November 15th, 2011
After SATURN, What Role for Rosuvastatin? A CardioExchange Panel
CardioExchange Editors, Staff
With the publication and presentation of negative data from the SATURN trial (see our news summary), CardioExchange convened a panel to answer this question: In light of the data from SATURN and the impending arrival of generic atorvastatin, what is the appropriate role of rosuvastatin at this point? Steven E. Nissen, MD (senior author of […]
November 15th, 2011
After AIM HIGH, What Future for Niacin? A CardioExchange Panel
CardioExchange Editors, Staff
Steve Nissen, JoAnne Foody, Roger Blumenthal, and AIM HIGH author William Boden weigh in on what patients do and don’t remain good candidates for niacin therapy.
November 15th, 2011
Hype Aside, Hope for Stem Cell Therapy May Be Emerging from Hibernation
Larry Husten, PHD
Two small studies of cardiac stem cells for the treatment of heart failure have shown promise, but ABC News, CBS News, and other media outlets are throwing around words like “medical breakthrough” and “heart failure cure.” ABC News correspondent Richard Besser was so enthusiastic that anchor Diane Sawyer commented that she had never seen him “so excited.” […]
November 15th, 2011
MI FREE: A Free Lunch for Patients and Insurers Alike?
John Ryan, MD
Removing copays increased adherence, decreased events, and saved the sponsoring insurance company a tidy sum. So are the issues with insurance-sponsored studies different from those with pharmaceutical-sponsored ones?
November 15th, 2011
Go Red: Highlights from the Women and Heart Disease Session
Reva Balakrishnan, MD, MPH
Fascinating data on clinical and psychosocial aspects of heart disease in women
November 15th, 2011
My First Oral Presentation: Life on the Other Side of the Podium
Amit Shah, MD, MSCR
Not having to drag around a poster container was refreshing, but instead I found myself dragging around my dread about my oral presentation.
November 15th, 2011
Finding Wisdom in Unfamiliar Ways in a Familiar Place
Amit Shah, MD, MSCR
The Scientific Sessions are not the only way to learn at AHA.
November 15th, 2011
SATURN Regression Trial: Gorilla Statin and Statin King Battle to a Draw
Larry Husten, PHD
An epic battle comparing the two most potent statins — the reigning king atorvastatin versus “gorilla statin” rosuvastatin — has ended with a quiet draw. Results of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin Versus AtorvastatiN) were presented at the AHA on Tuesday and published simultaneously in the New England Journal of Medicine. Stephen Nicholls and colleagues randomized […]
November 15th, 2011
AIM-HIGH: No Benefit for Niacin on Top of Statins
Larry Husten, PHD
The AIM-HIGH investigators aimed for the lofty target of proving the beneficial effects of niacin therapy. They did not succeed. Their findings were presented Tuesday morning at the AHA and published simultaneously in the New England Journal of Medicine. In AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes), […]
November 14th, 2011
PALLAS Intrigue: What Role Remains for Dronedarone?
CardioExchange Editors, Staff
John Mandrola, Eric Prystowsky, and Sanjay Kaul weigh in on PALLAS and the present and future of Multaq.